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Abstract
Background: Topiramate is approved for the prophylaxis (prevention) of migraine headache in
adults. The most common adverse events in the three pivotal, randomized, double-blind, placebo-
controlled trials were paresthesia, fatigue, cognitive impairment, anorexia, nausea, and taste
alteration. In these trials, topiramate 100 mg/d significantly improved Migraine-Specific
Questionnaire (MSQ) scores versus placebo (p < 0.001). The MSQ measures how much migraine
limits/interrupts daily performance. Pooled analyses of pivotal trial data were conducted to further
assess how topiramate 100 mg/d affects daily activities and patient functioning.
Methods: Mean MSQ and Medical Outcome Study Short Form 36 (SF-36) change scores (baseline
to each double-blind assessment point) were calculated for pooled intent-to-treat (ITT) patients.
Additionally, pooled ITT patients receiving topiramate 100 mg/d or placebo were combined and
divided into two responder groups according to percent reduction in monthly migraine frequency:
< 50% responders or ≥ 50% responders. Between-group differences were assessed using analysis
of covariance.
Results: Of 756 patients (mean age 39.8 years, 86% female), 384 received topiramate 100 mg/d
and 372 placebo. Topiramate significantly improved all three MSQ domains throughout the double-
blind phase versus placebo (p = 0.024 [week 8], p < 0.001 [weeks 16 and 26] for role prevention;
p < 0.001 for role restriction and emotional function [all time points]). Topiramate 100 mg/d
significantly improved SF-36 physical component scores (PCS) throughout the double-blind phase
versus placebo (p < 0.001, all time points) and significantly improved mental component scores
(MCS) at week 26 (p = 0.043). The greatest topiramate-associated improvements on SF-36
subscales were seen for bodily pain and general health perceptions (p < 0.05; weeks 8, 16, and 26),
and physical functioning, vitality, role-physical, and social functioning (p < 0.05; weeks 16 and 26).
Significantly greater improvements in all three MSQ domains, as well as the PCS and MCS of SF-36,
were observed for ≥ 50% responders versus < 50% responders (p < 0.001). Significantly greater
Published: 4 October 2007
Health and Quality of Life Outcomes 2007, 5:56 doi:10.1186/1477-7525-5-56
Received: 14 March 2007
Accepted: 4 October 2007
This article is available from: http://www.hqlo.com/content/5/1/56
© 2007 Dahlöf et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Health and Quality of Life Outcomes 2007, 5:56 http://www.hqlo.com/content/5/1/56
Page 2 of 10
(page number not for citation purposes)
percentages of topiramate-treated patients were ≥ 50% responders versus placebo (46% versus
23%; p < 0.001).
Conclusion: Topiramate 100 mg/d significantly improved daily activities and patient functioning at
all time points throughout the double-blind phase. Daily function and health status significantly
improved for those achieving a ≥ 50% migraine frequency reduction.
Introduction
Migraine is a significant detriment to daily functioning
and productivity during, but also to a certain extent before
and after, attacks. Migraine preventive therapy should
improve negative, disease-related outcomes, provided
that appropriate diagnostic criteria and management
guidelines are followed. Although approximately 11.5
million U.S. patients with migraine could benefit from
preventive therapy (approximately 40% of all U.S.
patients with migraine), only one in five currently receives
this type of treatment [1,2].
In three large, randomized, double-blind, placebo-con-
trolled, 6-month, migraine prevention trials [3-6], topira-
mate 100 mg/d (50 mg bid) was associated with a
significant and sustained decrease in mean monthly
migraine frequency, observed as early as the first month of
therapy. Topiramate 100 mg/d was generally well toler-
ated and is recommended as the target dose for most
patients with migraine [3-6]. Recently, safety and tolera-
bility data for these three trials was pooled and analyzed
[6]. The most common adverse events in topiramate-
treated patients in these trials were paresthesia (50.5%),
fatigue (15.0%), anorexia (14.5%), upper respiratory
infection (14.0%), cognitive impairment (13.7%), nausea
(13.2%), diarrhea (11.1%), and weight decrease (9.1%).
Adverse events were mostly mild to moderate in severity
and occurred more frequently during titration to target
doses [7]. For a more detailed analysis of safety and toler-
ability data, the published trials can be reviewed [3-5].
Pooled Migraine-Specific Questionnaire (MSQ) data from
the three pivotal trials showed that topiramate 100 mg/d
significantly improved each of the three dimensions of
MSQ at end point compared with placebo [8]. In addi-
tion, analyses of the effects of topiramate migraine pre-
ventive therapy on the two activity-related domains of the
MSQ and the Medical Outcomes Study Short Form-36
(SF-36), prospectively designated as outcome measures in
the North American pivotal trials, were recently published
[9,10]. Improvements in patient-reported MSQ outcomes
were significantly better for patients receiving topiramate
than for those receiving placebo. In addition, improve-
ments in the selected MSQ and SF-36 domains were sig-
nificantly correlated with the decrease in mean monthly
migraine frequency observed with topiramate treatment
[9,10].
To further assess the impact of topiramate on daily activi-
ties and function over time, results derived from both the
MSQ and the generic SF-36 were analyzed over the three
time points during the 26-week double-blind phase when
the questionnaires were administered. Additionally, we
sought to determine the relationship between improve-
ment in these quality of life measures and reductions in
migraine frequency.
Methods
Study design
The overall study design for patients receiving topiramate
100 mg/d or placebo in the three similar placebo-control-
led pivotal trials has been described previously [3-5].
Patients
Patients were required to have three to 12 migraine peri-
ods (one period equals 24 hours with migraine; ie,
migraine frequency) and no more than 15 headache days
during the 28-day prospective baseline phase. Patients
were allowed to continue taking specific agents for acute
treatment of migraine, but those who overused acute
medications were excluded from the placebo-controlled
trials [3,4], except in the trial with propranolol as an active
comparator [5]. The intent-to-treat (ITT) population was
identified as those who received ≥ 1 post-baseline dose of
study medication and contributed efficacy data during the
double-blind phase. Demographics for the pooled ITT
population are presented in Table 1.
Outcome measures
MSQ and SF-36 data were collected at baseline and at
weeks 8, 16, and 26. End point was defined as the last
available post-baseline observation in the double-blind
phase. The 14-item MSQ assesses the degree to which
migraine limits and interrupts daily performance and is
divided into three domains: Role Restriction assesses the
degree to which migraine limits performance of daily life,
social life, and work (seven questions); Role Prevention
assesses the degree to which migraine prevents perform-
ance of daily life, social life, and work (four questions);
and Emotional Function measures the feeling of frustra-
tion and helplessness as a result of migraine (three ques-
tions). All three MSQ domains are scored from 0 to 100,
with a higher score indicating better functioning [11]. The
reliability and validity of the MSQ has been demonstrated
in numerous studies [11-13].H
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Table 1: Baseline demographics for the intent-to-treat populations from the three pivotal migraine prevention trials
Pivotal Topiramate Trials
Silberstein 2004 [3] Brandes 2004 [4] Diener 2004 [5] Pooled
Placebo Topiramate 100 mg/d Placebo Topiramate 100 mg/d Placebo Topiramate 100 mg/d Placebo Topiramate 100 mg/d P value*
No. of Patients (completers) 115 (69) 125 (83) 114 (63) 120 (63) 143 (99) 139 (94) 372 (231) 384 (240)
Age, Mean ± SD (yrs) 40.4 ± 11.5 40.6 ± 11.0 38.3 ± 12.0 39.1 ± 12.6 40.4 ± 10.1 39.8 ± 10.9 39.8 ± 11.1 39.8 ± 11.5 0.939
Female, n (%) 103 (90%) 112 (90%) 94 (82%) 109 (91%) 109 (76%) 110 (79%) 306 (82%) 331 (86%) 0.160
Caucasian, n (%) 107 (93%) 117 (94%) 101 (89%) 108 (90%) 127 (89%) 122 (88%) 335 (90%) 347 (90%) 0.965
*p value is from analysis of variance model with treatment and study as fixed factors for age comparison; p values are from Cochran-Mantel-Haenszel general association test controlling for study for 
gender and race comparisons.Health and Quality of Life Outcomes 2007, 5:56 http://www.hqlo.com/content/5/1/56
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The generic SF-36 is a widely used, validated tool that
assesses the general impact of medical disorders on multi-
ple domains of patient daily activities and function. It
consists of two aggregate summary measures (scales) and
eight domain-specific measures (subscales) and is scored
from 0 to 100, with a higher score indicating greater func-
tion. A change of five points on the SF-36 is generally con-
sidered clinically meaningful.
The change in mean MSQ or SF-36 scores from baseline
through the double-blind phase was assessed for pooled
ITT patients. Baseline values for MSQ and SF-36 are sum-
marized in Table 2. In an additional analysis reflecting
International Headache Society clinical trial guidelines,
pooled ITT patients on topiramate 100 mg/d or placebo
were combined and divided into groups based on
whether they had experienced ≥ 50% or < 50% reductions
in monthly migraine frequency at the study end point.
Changes in MSQ and SF-36 scores from baseline to end
point were compared between these responder groups.
Statistical analysis
Between-group differences were analyzed using an analy-
sis of covariance model, with treatment and protocol as
main effects and respective baseline values as covariates.
The responder rate was analyzed using the Cochran-Man-
tel-Haenszel test adjusting for protocol and analysis
center. For these exploratory post hoc analyses, the statis-
tical methodologies used to assess differences between
groups were not adjusted for multiplicity. Descriptive sta-
tistics were used for the demographic analysis.
Results
Demographic and baseline characteristics of patients
Demographics and baseline MSQ and SF-36 scores for the
pooled ITT population are presented in Tables 1 and 2. A
total of 756 patients given topiramate 100 mg/d (n = 384)
or placebo (n = 372) were included in this analysis. The
mean (± SD) ages of the patients in these trials ranged
from 38.3 (± 12.0) years to 40.6 (± 11.0) years (range, 12
to 70 years). The majority of patients in the three trials
were female (≥ 76%) and Caucasian (≥ 88%). The mean
(± SD) MSQ scores at baseline (± SD) ranged from 48.1 (±
17.2) to 68.6 (± 18.9). The mean (± SD) SF-36 scores at
baseline ranged from 42.9 (± 9.1) to 82.1 (± 19.4). Pooled
ITT patients receiving topiramate 100 mg/d or placebo
were combined and divided into two response groups <
50% response (n = 492) or ≥ 50% response (n = 262).
Outcome measures
MSQ scores
Topiramate 100 mg/d significantly improved the mean
scores from baseline for all three domains (Role Restric-
tion, Role Prevention, and Emotional Function) of the
MSQ at weeks 8, 16, and 26, and at end point compared
with placebo (p < 0.001 for all, except Role Prevention p
= 0.024 at week 8) (Figures 1, 2, 3).
Table 2: Migraine-Specific Questionnaire (MSQ) and Medical Outcome Study Short Form 36 (SF-36) baseline scores for the pooled 
intent-to-treat population
Baseline Scores (Mean ± SD)
MSQ Domains Placebo (n = 372) Topiramate 100 mg/d (n = 384) p value*
Role Restriction 51.6 ± 16.2 48.1 ± 17.2 0.008
Role Prevention 68.6 ± 18.9 67.0 ± 19.4 0.285
Emotional Function 57.1 ± 22.7 53.7 ± 24.2 0.087
SF-36 Domains Baseline Scores (Mean ± SD)
Placebo (n = 372) Topiramate 100 mg/d (n = 384) p-value
Physical Functioning 82.0 ± 20.1 82.1 ± 19.4 0.920
Bodily Pain 51.3 ± 22.9 51.5 ± 22.4 0.969
Vitality 51.3 ± 19.4 50.8 ± 20.8 0.891
General Health 68.0 ± 19.5 68.8 ± 20.2 0.593
Role-Emotional 69.0 ± 39.3 70.9 ± 37.7 0.486
Role-Physical 44.5 ± 39.9 44.2 ± 40.8 0.959
Mental Health 70.7 ± 17.7 71.4 ± 16.7 0.483
Social Functioning 68.5 ± 22.3 70.0 ± 23.5 0.331
Physical Component Summary 43.1 ± 8.6 42.9 ± 9.1 0.767
Mental Component Summary 46.9 ± 10.6 47.5 ± 10.2 0.396
*p values are from analysis of variance model with treatment and study as fixed factors.Health and Quality of Life Outcomes 2007, 5:56 http://www.hqlo.com/content/5/1/56
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SF-36 scores
Topiramate treatment resulted in significant improve-
ment compared with placebo at week 26 on all SF-36 sub-
scales except Role-Emotional (Figure 4, Table 3).
Topiramate treatment significantly improved the SF-36
physical component scores throughout the double-blind
phase compared with placebo (p < 0.001, all time points)
and significantly improved the mental component scores
at week 26 (p = 0.043). Maximal topiramate-associated
improvements on SF-36 subscales were seen for Bodily
Pain and General Health Perceptions (p < 0.05; weeks 8,
16, and 26) and Physical Functioning, Vitality, Role-Phys-
ical, and Social Functioning (p < 0.05; weeks 16 and 26).
Responder analysis
Significantly greater percentages of patients on topiramate
100 mg/d were ≥ 50% responders versus placebo (46%
versus 23%; p < 0.001, Cochran-Mantel-Haenszel test).
The individual responder rates for the three pivotal stud-
ies were: 54.0% versus 22.6% placebo (p < 0.001) in Sil-
berstein et al. [3]; 49% vs. 23% placebo (p < 0.001) in
Brandes et al. [4]; and 37% versus 22% placebo (p < 0.01)
in Diener et al. [5]. Baseline MSQ and SF-36 domain
scores for those ITT patients who experienced ≥ 50% or <
50% reductions in monthly migraine frequency at end
point (last observation carried forward), regardless of
study medication, are presented in Table 4; scores were
generally similar between the two responder groups. The
≥ 50% responders had significantly higher improvements
from baseline to double-blind end point for all three MSQ
domains compared with the < 50% responders (Figure 5;
p < 0.001). In addition, the ≥ 50% responders had signif-
icantly improved SF-36 Physical Component Summary
and Mental Component Summary scores and signifi-
cantly improved scores on seven of eight SF-36 subscales
at end point compared with the < 50% responders (Figure
6). Of 262 patients identified as responders, 177 (67.6%)
were given topiramate and 85 (32.4%) were on placebo.
Time course of improvement – Emotional function: mean  change from baseline in Migraine-Specific Questionnaire  (MSQ) domain scores Figure 3
Time course of improvement – Emotional function: mean 
change from baseline in Migraine-Specific Questionnaire 
(MSQ) domain scores. *p < 0.001, †p = 0.024 versus placebo. 
EP = end point; LOCF = last observation carried forward; 
TPM = topiramate.
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Time course of improvement – Role restriction: mean  change from baseline in Migraine-Specific Questionnaire  (MSQ) domain scores Figure 1
Time course of improvement – Role restriction: mean 
change from baseline in Migraine-Specific Questionnaire 
(MSQ) domain scores. *p < 0.001, †p = 0.024 versus placebo. 
EP = end point; LOCF = last observation carried forward; 
TPM = topiramate.
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Time course of improvement – Role prevention: mean  change from baseline in Migraine-Specific Questionnaire  (MSQ) domain scores Figure 2
Time course of improvement – Role prevention: mean 
change from baseline in Migraine-Specific Questionnaire 
(MSQ) domain scores. *p < 0.001, †p = 0.024 versus placebo. 
EP = end point; LOCF = last observation carried forward; 
TPM = topiramate.
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Discussion
Studies detailing the specific impact of migraine preven-
tive therapy on daily activities are limited despite the obvi-
ous clinical relevance of such information. The results of
this analysis of pooled MSQ and SF-36 data from three
pivotal topiramate migraine prevention trials demon-
strated that topiramate 100 mg/d was associated with a
significant and sustained improvement in daily activities
and function for up to 6 months. All MSQ domain scores
were significantly improved by week 8 (first health-related
quality-of-life assessment point post baseline). The MSQ
results indicated that patients on topiramate 100 mg/d
had significantly less migraine-related disruption of daily
activities and less frustration and feelings of helplessness
due to migraine than those on placebo. Topiramate 100
mg/d was also associated with significant improvements
in seven of eight subscales of the SF-36. Topiramate-asso-
ciated improvements on the disease-specific MSQ were
stronger than the generic SF-36 scale, which is not surpris-
ing given that generic scales tend to measure constructs
that are not necessarily affected by a specific disease. In
addition, the MSQ does not fully assess the impact of
adverse events of drug treatment and may contribute to
the higher change scores observed following topiramate
treatment.
The Genetic Epidemiology of Migraine study revealed that
patient function was inversely related to migraine attack
frequency (p < 0.0002), with those suffering from a high
frequency of attacks reporting diminished physical, men-
tal, and social functioning [14]. In this analysis, patients
who experienced ≥ 50% decreases in monthly migraine
frequency on either topiramate or placebo (≥ 50%
responders) experienced significantly more improvement
in their functioning levels than those patients who experi-
enced < 50% decreases in monthly migraine frequency.
This result indicates that reduced monthly migraine fre-
quency is associated with improved patient ability to carry
out daily activities, a result supported by earlier clinical
trials [6]. Active treatment is superior to placebo, with
topiramate 100 mg/d associated with a significantly
higher percentage of ≥ 50% responders (46%) than pla-
cebo (23%, p < 0.001, Cochran-Mantel-Haenszel test) in
Table 3: Change from baseline over time in Medical Outcome Study Short Form 36 (SF-36) domain scores
SF-36 Domain Treatment Group Week 8 Week 16 Week 26 End Point
Physical Functioning Placebo 3.2 ± 0.8 3.2 ± 0.9 5.0 ± 1.0 3.6 ± 0.9
Topiramate 4.8 ± 0.8 6.4 ± 0.9 8.3 ± 1.0 5.3 ± 0.8
NS p = 0.025 p = 0.023 NS
Bodily Pain Placebo 6.2 ± 1.2 6.7 ± 1.3 6.7 ± 1.4 4.6 ± 1.2
Topiramate 12.0 ± 1.1 14.3 ± 1.4 14.5 ± 1.4 11.5 ± 1.2
p < 0.001 p < 0.001 p < 0.001 p < 0.001
Vitality Placebo 1.9 ± 1.0 3.1 ± 1.0 3.9 ± 1.2 1.8 ± 1.0
Topiramate 3.8 ± 1.0 7.9 ± 1.1 10.1 ± 1.2 5.2 ± 1.0
NS p = 0.008 p < 0.001 p = 0.035
General Health Placebo 1.0 ± 0.7 0.4 ± 0.8 1.6 ± 0.9 0.8 ± 0.8
Topiramate 3.4 ± 0.7 4.3 ± 0.9 4.5 ± 0.9 2.2 ± 0.8
p = 0.009 p < 0.001 p = 0.027 NS
Role- Emotional Placebo 4.5 ± 2.0 4.1 ± 2.1 6.5 ± 2.3 3.0 ± 2.0
Topiramate 2.2 ± 2.0 8.0 ± 2.2 9.3 ± 2.3 2.3 ± 2.0
NS NS NS NS
Role- Physical Placebo 14.4 ± 2.2 15.0 ± 2.2 15.9 ± 2.5 12.0 ± 2.1
Topiramate 19.3 ± 2.2 26.6 ± 2.4 24.1 ± 2.5 17.9 ± 2.1
NS p < 0.001 p = 0.018 NS
Mental Health Placebo -0.2 ± 0.9 0.8 ± 0.8 0.6 ± 1.0 -0.2 ± 0.9
Topiramate -1.5 ± 0.9 2.9 ± 0.9 3.2 ± 1.0 -0.5 ± 0.9
NS NS p = 0.034 NS
Social Functioning Placebo 5.3 ± 1.2 7.8 ± 1.2 6.8 ± 1.3 4.8 ± 1.2
Topiramate 4.8 ± 1.2 8.5 ± 1.3 10.8 ± 1.3 4.8 ± 1.2
NS NS p = 0.010 NS
Physical Component Summary Placebo 2.8 ± 0.4 2.8 ± 0.4 3.2 ± 0.5 2.5 ± 0.4
Topiramate 5.1 ± 0.4 5.7 ± 0.5 5.7 ± 0.5 4.7 ± 0.4
p < 0.001 p < 0.001 p < 0.001 p < 0.001
Mental Component Summary Placebo 0.3 ± 0.6 0.8 ± 0.5 0.9 ± 0.6 0.1 ± 0.5
Topiramate -0.6 ± 0.6 1.5 ± 0.6 2.2 ± 0.6 -0.2 ± 0.5
NS NS p = 0.043 NSHealth and Quality of Life Outcomes 2007, 5:56 http://www.hqlo.com/content/5/1/56
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Table 4: Mean Migraine-Specific Questionnaire (MSQ) and Medical Outcome Study Short Form 36 (SF-36) scores at baseline for 
pooled intent-to-treat (ITT) subjects with < 50% and ≥ 50% reductions in monthly migraine frequency, regardless of study medication*
< 50% Responders ≥ 50% Responders
MSQ Domain n Baseline n Baseline
Emotional Function 455 55.5 244 55.2
Role Prevention 454 68.3 243 67.0
Role Restriction 455 50.1 244 49.4
SF-36 Subscale n Baseline n Baseline
Physical Functioning 454 83.1 243 80.3
B o d i l y  P a i n 4 5 35 1 . 42 4 45 1 . 6
V i t a l i t y 4 5 45 1 . 72 4 35 0 . 0
General Health 447 68.4 242 68.3
Role-Emotional 453 71.0 240 68.2
Role Physical 452 44.6 241 44.1
Mental Health 454 71.3 243 70.7
Social Functioning 455 69.8 244 68.6
Physical Component Score 439 43.2 237 42.8
Mental Component Score 439 47.4 237 46.9
*N values reflect the numbers of patients with evaluable data on each domain, not the ITT population.
Radar plots of absolute mean Medical Outcome Study Short Form 36 (SF-36) scores at baseline and week 26 Figure 4
Radar plots of absolute mean Medical Outcome Study Short Form 36 (SF-36) scores at baseline and week 26. PBO = placebo; 
TPM = topiramate; PF = physical functioning; BP = bodily pain; VT = vitality; GH = general health perceptions; RE = role-emo-
tional; RP = role-physical; MH = mental health; SF = social functioning; ITT = intent-to-treat; TPM = topiramate. All p values 
versus PBO from baseline to week 26: PF, p = 0.023; BP, p < 0.001; VT, p < 0.001; GH, p = 0.027; RP, p = 0.018); MH, p = 
0.034; SF, p = 0.010.
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Migraine-Specific Questionnaire (MSQ) domain scores at end point (last observation carried forward) for pooled intent-to- treat subjects with ≥ 50% or < 50% reductions in monthly migraine frequency Figure 5
Migraine-Specific Questionnaire (MSQ) domain scores at end point (last observation carried forward) for pooled intent-to-
treat subjects with ≥ 50% or < 50% reductions in monthly migraine frequency.
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a pooled analysis of randomized, double-blind, placebo-
controlled trials [6].
The results of this post-hoc study are consistent with pre-
specified analyses from two trials that evaluated MSQ and
SF-36 outcomes to measure changes in daily activities and
function related to topiramate treatment [9,10]. Results of
an analysis conducted by Silberstein and colleagues found
that in the ITT population (N = 469), topiramate (50 mg/
d, 100 mg/d, and 200 mg/d) significantly improved mean
MSQ Role Restriction domain scores versus placebo (p =
0.035; p < 0.001; p = 0.001, respectively) [9]. Improve-
ments in mean MSQ Role Prevention scores were signifi-
cant versus placebo only for topiramate 100 mg/d (p =
0.045). SF-36 Role-Physical and SF-36 Vitality domain
scores chosen as outcome measures improved but were
not significant versus placebo for topiramate 100 mg/d
and 200 mg/d. Changes in these MSQ and SF-36 domain
scores significantly correlated with changes in mean
monthly migraine frequency.
In an analysis conducted by Brandes and colleagues [10],
patients receiving topiramate, 100 or 200 mg/d, had sig-
nificantly reduced mean monthly migraine frequency (p =
0.008 and p < 0.001, respectively) compared with pla-
cebo, but not patients receiving topiramate 50 mg/d (p =
0.48). Topiramate significantly improved mean MSQ
Role Restriction domain scores (50 mg/d [p = 0.02], 100
mg/d [p < 0.001], and 200 mg/d [p < 0.001]) and mean
MSQ Role Prevention domain scores (50 mg/d [p =
0.007], 100 mg/d [p = 0.001], and 200 mg/d [p = 0.002])
versus placebo. Topiramate 100 and 200 mg/d signifi-
cantly improved mean SF36 Role-Physical domain scores
versus placebo (p = 0.02). Changes in prospectively desig-
nated domain scores were significantly correlated with
changes in mean monthly migraine frequency (p ≤ 0.001,
MSQ domains; p ≤ 0.002, SF-36 domains).
Conclusion
The results of this study demonstrate that preventive treat-
ment of migraine with topiramate 100 mg/d improves
patients' ability to carry out daily activities as early as week
8, and the effect is maintained during 6-month treatment.
Information about such patient-centered outcomes is
likely to be of interest to migraine patients and clinicians
making treatment decisions, but has not been routinely
evaluated for most migraine preventive treatments.
Reducing the considerable burden and disability of
migraine through effective treatment may improve
patients' overall functional capacity.
Abbreviations
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